THE ADVANTAGES OF USING FIXED COMBINATIONS OF ANTIHYPERTENSIVE DRUGS IN CLINICAL PRACTICE


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article considers the main problems of drug therapy in patients with arterial hypertension (AH) in the present stage of development of hypertensiology: extensive comorbidity, induced polypharmacy, drug interactions, low adherence to treatment. The important role of the use of combination therapy and especially fixed combinations of antihypertensive drugs in solving important issues of effective and safe antihypertensive therapy is emphasized. Particular attention is paid to one of the most rational fixed combinations of antihypertensive drugs - combination of ACE inhibitor and dihydropyridine calcium antagonist Data on the results of clinical trials (randomized or prospective and retrospective observational studies, registers of patients with hypertension) on the efficacy and safety of fixed-combination therapy of ramipril and amlodipine are presented, as well as consideration of various aspects of patient adherence to treatment.

Texto integral

Acesso é fechado

Sobre autores

Yulia Lukina

National Medical Research Center for Preventive Medicine

Email: yuvlu@mail.ru
MD, PhD, Leading Researcher, Department of Preventive Pharmacotherapy Petroverigsky per. 10, Moscow, 101990, Russia

Bibliografia

  1. ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013;34:2159-219.
  2. Lukina Y.V., Martsevich S.Y. Combination therapy of hypertension - a reliable way to target achieve. Rational Pharmacotherapy in Cardiology. 2010;6(6):859-864.
  3. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J.; ASCOT Investigators. Prevention of cardiovascular events with with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
  4. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., Hester A., Gupte J., Gatlin M., Velazquez E.J. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008;359:2417-28.
  5. Oganov R.G., Pogosova G.V., Koltunov I.E., et al. RELIFE - Regular Treatment and Prophylaxis - the Key to Improving the Situation of Cardiovascular Diseases in Russia: the Results of a Russian Multicenter Study. Part III. Cardiology. 2008;48(4):46-53.
  6. Kontsevaya A.V., Romanenko T.S., Vygodin V.A., Fitilev S.B. Рharmacoepidemiology and the efficacy of antihypertensive treatment in real-life practice of the cardiology referral clinic. Rational Pharmacotherapy in Cardiology. 2015 ; 11 ( 1 ) :8-17.
  7. Leonova M.L., Shteinberg L.L., Belousov Yu.B. and a group of researchers. Pharmacoepidemiology of arterial hypertension in Russia: an analysis of physicians' adherence (based on the results of the PIFAGOR IV study). Systemic hypertension. 2015; 1:19-25.
  8. Kaplan N.M. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996;18(4):658-70.
  9. Marre M., Lievre M., Chatellier G., Mann J.F., Passa P., Ménard J.; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328(7438):495.
  10. Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. 2004;17(5):259-66.
  11. Agabiti-Rosei E., Ambrosioni E., Dal Palù C., Muiesan M.L., Zanchetti A. ACE inhibitor ramipril is more effective than the betablocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (RAmipril Cardioprotective Evaluation) study. J. Hypertens. 1995;13(11):1325-34.
  12. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000;342(3):145-53.
  13. The top 50 prescription drugs filled in the U.S. Consumers, Drugs, Healthcare Professionals, Industry News. Jun 16, 2016. Available at https://www.lowestmed.com/top-50-prescription-drugs-filled/
  14. Martsevich S.Y., Lukina Y.V., Zagrebelnyy A.V., Loukianov M.M., Vorobyev A.N., Pravkina E.A., Myasnikova N.O. Combined antihypertensive therapy in real clinical practice. focus on fixed combinations of antihypertensive drugs (According to the Data of Outpatient Registries RECVASA and PROFILE). Rational Pharmacotherapy in Cardiology. 2017; 13(3):323-9.
  15. Miranda R.D., Mion D. Jr, Rocha J.C., Kohlmann O. Jr, Gomes M.A., Saraiva J.F., Amodeo C., Filho B.L. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin. Ther. 2008;30(9):1618-28.
  16. Lauer M.S., D'Agostino R.B. Sr. The randomized registry trial--the next disruptive technology in clinical research? N. Engl. J. Med. 2013;369(17):1579-81.
  17. Tomcsanyi J. Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fixed combination - a noninterventional trial (RAMONA study). Abstract in engl. [A ramipril-amlodipin fi x kombinacio vernyomascsökkentö hatasanak monitorozasa - nem intervencios vizsgalat (RAMONA vizsgalat).] Hypertonia és Nephrologia, 2013;17:34-8. [Hungarian]
  18. Simonyi G. Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. 2016;129(10):1224-8.
  19. Simonyi G., Ferenci T. Medication adherence with the fixed combination of ramipril and amlodipine. Orv. Hetil. 2014;155(47):1882-8.
  20. Simonyi G., Ferenci T., Alfoldi S., Farsang C. Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. J. Int. Med. Res. 2016;44(5):1087-91
  21. Martsevich S.Y., Lukina Yu.V., Kutishenko N.P., et al. Study of adherence to therapy in patients with metabolic syndrome with the example of a new combination antihypertensive drug ramipril and amlodipine (based on the results of the observational study "GRANAT-1." Cardiovascular therapy and prevention. 2017; 16 (1):67-73.
  22. Martsevich S.Y., Lukina Yu.V., Kutishenko N.P., et al. Study of tolerability parameters and adherence to therapy in patients with chronic obstructive pulmonary disease and arterial hypertension in the context of treatment with a fixed combination of ramipril and amlodipine (based on the results of the observational study "GRANAT-2"). Rational pharmacotherapy in cardiology 2017, 132 (2): 229-237.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies